General anesthetics, including etomidate, act by binding to and enhancing the function of GABA type A receptors (GABA A Rs), which mediate inhibitory neurotransmission in the brain. Here, we used a radiolabeled, photoreactive etomidate analog ([ 3 H]azietomidate), which retains anesthetic potency in vivo and enhances GABA A R function in vitro, to identify directly, for the first time, amino acids that contribute to a GABA A R anesthetic binding site. For GABA A Rs purified by affinity chromatography from detergent extracts of bovine cortex, [ 3 H]azietomidate photoincorporation was increased by GABA and inhibited by etomidate in a concentration-dependent manner (IC 50 ϭ 30 M). Protein microsequencing of fragments isolated from proteolytic digests established photolabeling of two residues: one within the ␣M1 transmembrane helix at ␣1Met-236 (and/or the homologous methionines in ␣2,3,5), not previously implicated in etomidate function, and one within the ␤M3 transmembrane helix at ␤3Met-286 (and/or the homologous methionines in ␤1,2), an etomidate sensitivity determinant. The pharmacological specificity of labeling indicates that these methionines contribute to a single binding pocket for etomidate located in the transmembrane domain at the interface between ␤ and ␣ subunits, in what is predicted by structural models based on homology with the nicotinic acetylcholine receptor to be a water-filled pocket ϳ50 Å below the GABA binding site. The localization of the etomidate binding site to an intersubunit, not an intrasubunit, binding pocket is a novel conclusion that suggests more generally that the localization of drug binding sites to subunit interfaces may be a feature not only for GABA and benzodiazepines but also for etomidate and other intravenous and volatile anesthetics.
Introduction
GABA type A receptors (GABA A Rs) are the molecular targets for general anesthetic action in the brain. Anesthetics of diverse chemical structure, including inhalants, neuroactive steroids, and intravenous general anesthetics such as etomidate, propofol, and barbiturates, all enhance GABA A R currents in vitro at doses consistent with their action as anesthetics in vivo (Olsen et al., 1986; Franks and Lieb, 1994; Yamakura et al., 2001; Hemmings et al., 2005) .
The GABA A R is a member of the Cys-loop superfamily of ligand-gated ion channels that also includes the nicotinic acetylcholine receptors (nAChRs), from which much of the general structure of this superfamily is inferred (Corringer et al., 2000; Sine and Engel, 2006) . Each receptor is composed of a pentamer of homologous subunits arranged around a central axis. Each subunit transmembrane domain (TMD) is a bundle of four ␣ helices (M1-4), with M2 from each subunit forming the wall of the ion channel. GABA A R homology models can be constructed by using the structures of the soluble snail acetylcholine binding protein structure (Brejc et al., 2001 ) and the Torpedo nAChR (Miyazawa et al., 2003) . The two transmitter binding sites are within the receptor extracellular domain at subunit interfaces (␤-␣ for GABA A R), and the benzodiazepine binding site is at the equivalent position at the ␣-␥ interface (Cromer et al., 2002; Ernst et al., 2005) . Mutational analyses have identified positions in the GABA A R TMD that are important for the GABA-enhancing effects of alcohols and volatile and intravenous anesthetics (Mihic et al., 1997; Olsen et al., 2004) , with a binding pocket proposed for volatile anesthetics inside the helical bundle of a given subunit involving residues M2-15 and M3-4, numbered relative to the N-terminal charge of each helix (Mihic et al., 1997; Yamakura et al., 2001 ). The M2-15 residue also determines the selectivity of ␤ subunits for etomidate in vitro , and a knock-in mouse for ␤3N265M shows reduced sensitivity to the anesthetic effects of etomidate and propofol (Jurd et al., 2003) .
In the absence of structural information, it remains uncertain whether these positions contribute directly to an anesthetic binding site or are involved in allosteric modulation of gating. Photoaffinity labeling, which provides an experimental approach to directly identify amino acids contributing to a drug binding site without previous assumptions about the protein points of contact (Kotzyba-Hibert et al., 1995) , has been used extensively to identify amino acids contributing to ligand binding sites in the Torpedo nAChR (Mourot et al., 2006) and for GABA A R agonists and benzodiazepines (Smith and Olsen, 1994; Duncalfe et al., 1996; Sawyer et al., 2002) . We now use 2-(3-methyl-3H-diaziren-3-yl) ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate ([ 3 H]azietomidate), a photoreactive analog of etomidate that retains anesthetic and GABA A R modulatory properties (Husain et al., 2003) , to provide the first identification of amino acids contributing to an anesthetic binding site in a GABA A R. The two labeled residues, ␣M1-14 (␣Met-236) and , are shown by homology modeling to border a pocket in the TMD located at the same subunit interfaces that contain the GABA binding site in the extracellular domain. The ␣M1 helix has not been implicated previously in etomidate function, whereas ␤M3-4 is an anesthetic sensitivity determinant (Mihic et al., 1997; Krasowski et al., 1998; Bali and Akabas, 2004) . Furthermore, the homology model suggests that this intersubunit etomidate binding pocket is in contact with ␤M2-15, an in vivo etomidate anesthetic sensitivity determinant (Jurd et al., 2003) .
Materials and Methods

Materials. [
3 H]azietomidate (11 Ci/mmol) was synthesized as described previously (Husain et al., 2003) . (Sources of antibodies and reagents are described in the supplemental Materials and Methods, available at www.jneurosci.org as supplemental material.)
Solubilization and purification of bovine brain GABA A Rs. GABA A R was purified by modification of previous protocols (Sigel and Barnard, 1984; Sawyer et al., 2002 ) on a benzodiazepine Ro7/1986-1 affinity column. Detailed conditions for solubilization and purification as well as the immunoblot and mass spectrometry protocols for characterization of the purified GABA A R are described in the supplemental Materials and Methods (available at www.jneurosci.org as supplemental material). Important modifications that allowed ϳ5000-fold purification of GABA A R at high yield and with retention of positive allosteric modulation of [ 3 H]muscimol binding by etomidate included: (1) the use of the detergent C 12 E 9 in conjunction with 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS) in the solubilization buffer; (2) extensive washing of the affinity resin with 10 mM CHAPS/ 0.06% asolectin/10% sucrose; and (3) elution with clorazepate, rather than flurazepam and urea. The binding of the GABA A R agonist [ 3 H]muscimol was assayed as described previously (Sawyer et al., 2002) . Photolabeling of purified GABA A R. The peak [ 3 H]muscimol binding fraction (5 ml) from each affinity column elution was used for labeling without further dialysis or concentration. KCl was added to a final concentration of 0.1 M. An aliquot of GABA A R (ϳ40 nM [ 3 H]muscimol binding sites; 2.5 ml for preparative labeling or 0.1-0.2 ml for analytical) was equilibrated with [ 3 H]azietomidate (final concentration, 1.5-3 M) plus or minus additional drugs, incubated on ice for 1 h in the dark (4°C), and irradiated (30 min; 365 nm). After photolabeling, the total protein was precipitated with methanol/chloroform, solubilized in sample loading buffer, and fractionated by SDS-PAGE. The resulting gel lane was cut into 3 mm slices and eluted individually in 1 ml of elution buffer (Ziebell et al., 2004) . The eluted bands were assayed for 3 H. Fractions of interest were filtered and concentrated, and the protein was precipitated with acetone and then resuspended in 50 l of digestion buffer (25 mM Tris, pH 8.6, 0.1% SDS, 500 M EDTA).
Enzymatic digestion, reversed-phase HPLC, and protein microsequencing. Digestion for 3 d at 25°C with the endoproteinases Lys-C (EndoLys-C) or Asp-N (EndoAsp-N) (Princeton Separations, Adelphia, NJ) was performed with 2.5 g of protease in 10 l of H 2 O added to 50 l of either labeled GABA A R in digestion buffer or, for EndoAsp-N, GABA A R diluted 10-fold with H 2 0 to reduce the SDS concentration to 0.01%. For V8 protease (ICN Biochemicals, Costa Mesa, CA), 100 g in 50 l was added to 50 l of labeled GABA A R. Reversed-phase HPLC and peptide microsequencing were performed as described previously (Ziebell et al., 2004) . For sensitive detection of 3 H release, the Procise 492 protein Sequencer (Applied Biosystems, Foster City, CA) was modified such that five-sixth of each cycle was collected for counting and one-sixth was injected for phenylthiohydantoin (PTH)-amino acid analysis. For high sensitivity detection of PTH-amino acids, two-thirds of each cycle was injected for PTH-amino acid analysis, and only one-third was counted. PTH-amino acids were quantitated by peak heights over background, and the actual picomole quantities and counts per minute that were detected are plotted in the figures. To determine the amount of peptide sequenced, the individual residues were fit to the equation I x ϭ I 0 ϫR x , where I x is the picomole quantity detected in cycle x, I 0 is the starting amount of the peptide, and R is the average repetitive yield. Treatment with o-phthalaldehyde (OPA) during sequencing was as described previously (Ziebell et al., 2004) . OPA reacts preferentially with primary rather than secondary amines (i.e., proline) and can be used at any cycle of Edman degradation to block sequencing of peptides not containing an N-terminal proline (Brauer et al., 1984) .
Molecular modeling. A homology model of a bovine GABA A R was constructed from the cryo-electron microscopy structure of the Torpedo marmorata nAChR [4 Å resolution; Protein Data Bank code 2BG9 (Unwin, 2005) ] with the Insight II Molecular Modeling package (Accelrys, San Diego, CA). The helical paths of the nAChR structure were preserved. Alignments of the M1, M2, and M4 segments relied on conserved residues in those sequences (Ernst et al., 2005) . The M3 alignment was poorly defined because there is no sequence conservation between the nAChR and GABA A R M3 segments. M3 was aligned in the nAChR structure to bring positions in ␣1M3 (Leu-300, Phe-303, and Ala-304) in proximity to ␣1Thr-267 (M2-12), consistent with cross-linking data (Jansen and Akabas, 2006) . The resulting M2-M3 loop extended from ␣1Pro-278 to ␣1Val-283. Potential ligand binding pockets were identified by the program PASS (Brady and Stouten, 2000) with 1.8 Å diameter probes.
Results
Purification of brain GABA A R with retention of allosteric modulation by etomidate
To identify the amino acids photolabeled by [ 3 H]azietomidate, we developed protocols for GABA A R solubilization and purification that preserved the binding of etomidate/azietomidate and allowed the ϳ5000-fold purification required for isolation of GABA A R at a high degree of purity. Previous studies had identified conditions by using strong detergents (deoxycholate and Triton X-100) and harsh washing steps that allowed several thousand-fold purification (to 1500 -3000 pmol [
3 H]muscimol per milligram of protein) while preserving agonist and benzodiazepine binding, but these preparations had lost allosteric modulation of benzodiazepine binding by barbiturates and anesthetic agents (Sigel et al., 1983; Stauber et al., 1987) . Allosteric modulation by barbiturates and etomidate are preserved by use of milder detergents such as CHAPS, but isolation of GABA A R at high purity and yield was problematic (Stephenson and Olsen, 1982; Sigel and Barnard, 1984; King et al., 1987) . As an alternative purification strategy, we examined whether the use of the detergent C 12 E 9 , which was particularly effective for purification of serotonin 5-HT 3 receptors (Hovius et al., 1998) , in conjunction with CHAPS would facilitate efficient purification of GABA A R with retention of allosteric modulation. We found that a combination of 4 mM C 12 E 9 and 5 mM CHAPS was most efficient: it solubilized 60% of the [ 3 H]muscimol binding sites, in contrast to the 30% solubilization by 17 mM CHAPS. The etomidate modulation of [ 3 H]muscimol binding seen for membrane suspensions was preserved after solubilization and also after purification by affinity chromatography (Fig. 1) . In each case, maximal potentiation was seen at 10 M etomidate, with half-maximal potentiation at 3 M, and etomidate at concentrations Ͼ10 M produced a progressive decrease of [ 3 H]muscimol binding. GABA A Rs in the detergent extracts were purified at high yield and ϳ5000-fold by use of a benzodiazepine Ro7/1986 -1 affinity column, extensive washing in the presence of 10 mM CHAPS/ 0.06% asolectin/10% sucrose, and elution with clorazepate. A representative purification (summarized in supplemental Table  1 , available at www.jneurosci.org as supplemental material) resulted in 720 pmol of GABA A R (55% yield), which bound 3.4 nmol [
3 H]muscimol per milligram of protein. The purified GABA A R was characterized by SDS-PAGE with protein stain and immunoblot (Fig. 2) . A single broad band centered at ϳ52 kDa was seen by Coomassie stain, but blots with subunit-specific antibodies revealed that the preparation consisted of a heterogeneous population of receptors. The peak of protein stain was closest to the molecular masses (kilodalton) of the antibodies specific for the ␣1(51), ␣2(53), ␤1(54), and ␤2(53) subunits, with the ␣3(59), ␣4(68), ␣5(57), and ␤3(56) subunits at lower mobility and ␥2(47) at higher mobility. This observed GABA A R heterogeneity, which was also confirmed by liquid chromatography mass spectrometry/mass spectrometry analysis (supplemental Fig. 1 , available at www.jneurosci.org as supplemental material), was expected, because the receptors were purified on a benzodiazepine affinity column that binds with high affinity all GABA A Rs containing the ␥2 subunit in combination with ␤ subunits and ␣1, ␣2, ␣3, or ␣5 subunits (Sieghart, 1995 H at ϳ52 kDa, corresponding to the peak of Coomassie stain and the gel region enriched in ␣1, ␣2, and ␤1-3 subunits. GABA (1 mM) increased labeling by ϳ50% (Fig. 2a) , and in the presence of GABA, etomidate produced a concentration-dependent inhibition of labeling characterized by an IC 50 value of 30 M, whereas the neurosteroid 3␣,5␣-tetrahydrodeoxycorticosterone (THDOC) (Wohlfarth et al., 2002) at 10 M did not inhibit photolabeling (Fig. 3) .
To begin to identify the photolabeled amino acids, 3 H release profiles were determined by Edman degradation of proteolytic digests of the GABA A R subunits eluted from gel bands containing the peak of 3 H (ϳ52 kDa) and from adjacent gel slices (ϳ58 kDa). Proteolytic fragmentation was performed with Lys-specific EndoLys-C (Fig. 4a) or with the Glu-specific Staphylococcus aureus endopeptidase Glu-C (Fig. 4b, V8 protease). For both EndoLys-C digests, there were peaks of 3 H release in cycles 7 and 14, with the 3 H releases reduced by Ͼ90% for digests from GABA A Rs labeled in the presence of 200 M etomidate (data not shown). For the samples digested with V8 protease, there were peaks of 3 H release in cycles 16 and 27. The releases of 3 H in cycle 7 of the EndoLys-C digest and cycle 16 of the V8 digest were most prominent in the digests of the 58 kDa band, whereas the 3 H releases in cycles 14 of the EndoLys-C digest and 27 of the V8 digest were dominant in the digests of the 52 kDa band. These were analyzed by SDS-PAGE, with the gel lanes cut into 3 mm slices to determine 3 H distribution by scintillation counting. The peak of 3 H, which was increased by 80% in the presence of GABA, had a mobility of 52 kDa that was similar to that of the Coomassie blue-stained band observed for a nonlabeled aliquot run on the gel in an adjacent lane (b, CBB). Also indicated are the relative positions of the molecular mass standards, which were shared by lanes in b. b, Coomassie stain and immunoblot characterization of aliquots of the same affinity column eluate fraction that was used for photolabeling. After electrophoretic transfer to polyvinylidene difluoride, strips were incubated with the indicated subunit-specific primary antibodies and then with secondary antibodies for visualization by chemiluminescence (see Materials and Methods). Shown are the results for a single experiment that was representative of results obtained with three different preparations of purified GABA A R. When EndoLys-C digests of each gel band were fractionated by reversed-phase HPLC, most of the 3 H eluted in a broad, hydrophobic peak (45-65% organic) (supplemental Fig. 2 , available at www. jneurosci.org as supplemental material). For the 52 kDa band, protein microsequencing of fractions containing 3 H identified fragments beginning near the N termini of the ␣M1, ␣M3, and ␣M4 membrane-spanning segments, as well as some ␤ subunit fragments (supplemental Fig. 1 and Table 2 , available at www. jneurosci.org as supplemental material). For the 58 kDa band, fragments containing ␤M3 and ␤M4 were identified.
The protein microsequencing established that [
3 H]azietomidate was incorporated into hydrophobic fragments, most likely one or several of the hydrophobic membrane spanning segments. Inspection of the location of potential EndoLys-C and V8 protease cleavage sites in terms of the subunit primary structures (Fig. 4c,d ) revealed that the 3 H release profiles observed during radiosequence analyses were consistent with the labeling of the following: (1) ␣1Met-236 (and/or ␣2Met-235, ␣3Met-260 , or ␣5Met-239), which is positioned in ␣M1 14 and 27 amino acids after ␣1Lys-222 and ␣1Glu-209, respectively; and (2) ␤1Met-286 (and/or ␤2Met-286 or ␤3Met-286), positioned in ␤M3, 7, and 16 amino acids after ␤Lys-279 and ␤Glu-270, respectively. Because of the high degree of sequence conservation in these regions, including the protease cleavage sites, the predicted labeled amino acids could not be assigned to specific subunit subtypes, and therefore they will be referred to as ␣Met-236 (using the ␣1 subunit numbering) and ␤Met-286.
[ 3 H]azietomidate labels ␣Met-236 and ␤Met-286
Labeling of ␣Met-236 and ␤Met-286 was confirmed by taking advantage of the presence of prolines at positions preceding the predicted labeled amino acids and of an established sequencing protocol in which OPA, which reacts with primary amines, is applied before a cycle containing a proline to prevent Edman degradation of all peptides without an N-terminal proline (Brauer et al., 1984; Middleton and Cohen, 1991) . When a sample from an HPLC purification of an EndoLys-C digest (Fig. 5a ) was sequenced with OPA treatment at the predicted cycle for ␣Pro-233, 3 H release was retained in cycle 14 (Fig. 5a) , as expected for labeling of ␣Met-236, and the PTHamino acids were present from the predicted fragment beginning at ␣Ile-223. Labeling of ␣Met-236 was also confirmed by sequencing a V8 digest with OPA treatment at the cycle appropriate for ␣Pro-233 (data not shown).
Sequence analysis of the 3 H peak from the HPLC purification of the EndoLys-C digest of the 58 kDa gel band identified a frag- 3 H release profiles observed after sequencing EndoLys-C (a) or V8 protease (b) digests of 52 kDa (black) or 58 kDa (gray) GABA A R subunits. Comparison of 3 H release profiles indicates that one labeled amino acid, detected primarily in the 52 kDa band, is 14/27 residues after a Lys/Glu, whereas the other is 7/16 residues after a Lys/Glu. c, d, Alignments of the bovine ␣M1 (c) and ␤M3 (d) sequences consistent with the 3 H release patterns illustrate homology between subtypes with conservation of labeling sites and protease sites (bold). 3 H release profiles (ϩGABA, F; ϪGABA, E), and picomoles of PTH-amino acid detected (ϩGABA only, Ⅺ) during Edman sequencing. a, Sequence analysis of the 3 H peak (3 fractions) from an HPLC purification (ϩGABA, 2430 cpm; ϪGABA, 1240 cpm) of an EndoLys-C digest of labeled GABA A R subunits (52-58 kDa) with OPA treatment in cycle 11. After OPA, sequencing persisted for the fragment beginning at ␣Ile233, the N terminus of ␣M1 (ϩGABA Ⅺ; I 0 , 1.3 pmol, R, 92%; ϪGABA, I 0 , 0.8 pmol, R, 95% (data not shown)]. Three additional sequences were present in the cycles before OPA: EndoLys-C Gly-1 (15 pmol), ␣Ile-392 (␣M4; 4 pmol), and ␣Val-280 (␣M3; 3 pmol). Treatment with OPA reduced levels of those peptides by Ͼ90%. The persistence of 3 H release in cycle 14 indicated labeling of ␣Met-236 (330 cpm/pmol ϩGABA; 180 cpm/pmol ϪGABA). b, Sequence analysis of the HPLC 3 H peak (ϩGABA, 580 cpm; ϪGABA, 320 cpm) from an EndoLys-C digest of labeled 58 kDa material identified fragments beginning at ␤Ala-280 (Ⅺ, ϩGABA, I 0 , 0.8 pmol, R, 92%; ϪGABA, I 0 , 0.5 pmol; R, 95%) as well as ␤3Ile-413 (␤M4; 0.5 pmol) and EndoLys-C Gly 1 (1.8 pmol). The 3 H release in cycle 7 was consistent with labeling of ␤Met-286 (120 cpm/pmol ϩGABA; 50 cpm/pmol ϪGABA). c, d, 3 H release after sequencing V8 protease digests of labeled GABA A R subunits (52-58 kDa) without further purification. The ␤Thr-271 sequence indicated above c is for reference but was not directly identified in these samples. Persistence of the 3 H release in cycle 16 after OPA treatment in cycle(s) 6 (c) or 3 and 6 (d) ment beginning at ␤Ala-280 as the primary GABA A R subunit sequence, with release in cycle 7 consistent with GABA-enhanced labeling of ␤Met-286 (Fig. 5b) . When samples from a V8 digest were sequenced with OPA treatment at the cycles predicted for ␤Pro-273 and ␤Pro-276,
3
H release was preserved in cycle 16, consistent with cleavage by V8 protease at ␤Glu-270 and labeling of ␤Met-286 (Fig. 5c,d ).
The efficiencies of GABA A R photolabeling (counts per minute/picomole) at ␣Met-236 and ␤Met-286 were estimated from the 3 H releases at the appropriate cycles of Edman degradation and the amount of ␣M1 or ␤M3 fragment detected during sequence analysis of the HPLC purified fragments from EndoLys-C digests of the 52 and/or 58 kDa gel bands (Fig. 5a,b ). The level of 3 H release in cycle 14 and the amount of the ␣M1 peptide indicated that ␣Met-236 was labeled at 330 (ϩGABA) and 180 cpm/pmol (ϪGABA) (Fig. 5a) . Based on the levels of 3 H release in cycle 7 and the amount of the ␤Ala-280 fragment in the samples (Fig. 5b) , ␤Met-286 was labeled at 120 (ϩGABA) and 50 cpm/pmol (ϪGABA), i.e., at ϳ30% the efficiency of labeling of ␣Met-236. The combined efficiency of labeling at these two amino acids was close to the GABA A R photolabeling efficiency [770 and 410 cpm/pmol (ϮGABA) 3 H]azietomidate in the presence of GABA, 3% of ␣Met-236 and 1% of ␤Met-286 were photolabeled. The efficiency of labeling will be determined both by the fractional site occupancy under our labeling conditions (ϳ10%, based on the IC 50 value of 30 M for etomidate inhibition of photolabeling) and the intrinsic reactivities of the binding site side chains relative to the rate of reaction of the reactive species with the primary scavenger, water. Additional labeling studies at higher concentrations, as have been performed for [
3 H]azietomidate labeling of the Torpedo nAChR (Ziebell et al., 2004) , will be required to determine the efficiency of labeling at higher site occupancy.
Labeling of ␤2/3Asn-265? Digestion of labeled GABA A R subunits with EndoLys-C or V8 protease cannot generate the cleavages necessary to identify labeling in ␤M2 at or near ␤2/3Asn-265, a major determinant of etomidate sensitivity in vitro and in vivo (Jurd et al., 2003; Reynolds et al., 2003) , because there are no lysines or glutamates in the ␤ subunit M1-M2 loop. The presence of an aspartate (␤3Asp-243) in the M1-M2 loop of each ␤ subunit, but not in the ␣ subunits, indicated that digestion with EndoAsp-N could potentially reveal labeling in ␤M2, and we could also determine whether the enzyme could cleave effectively at ␤Asp-280 at the N terminus of M3, which would result in 3 H release from the labeled ␤Met-286 in the fifth cycle of Edman degradation. Sequence analyses of labeled subunits digested with EndoAsp-N resulted in no 3 H release above background either in cycle 5 or in the later cycles that would contain ␤M2 (␤2/3Asn-265 would occur in cycle 21). The failure to observe 3 H release in cycle 5 indicated that under the conditions used, EndoAsp-N was not cleaving at ␤Asp-280, and there was also no evidence that it was cleaving in the M1-M2 loop. Additional studies are required to determine whether there is labeling in ␤M2 (or elsewhere in the GABA A R); however, as noted above, the combined labeling efficiencies at ␣Met-236 and ␤Met-286 (450 cpm/pmol ϩGABA) were close to the total GABA A R labeling (770 cpm/pmol ϩGABA), so there cannot be another amino acid labeled at higher efficiency.
Discussion
In this work, we provide a first identification by use of photoaffinity labeling of amino acids contributing to a binding site for a general anesthetic in the GABA A R, the in vivo target for the anesthetic action of etomidate. We used [ 3 H]azietomidate to photolabel GABA A Rs purified from bovine cortex and then identified by protein microsequencing two labeled amino acids, one in an ␣ subunit M1 membrane-spanning helix (␣Met-236) and the other in a ␤ subunit M3 membrane-spanning helix (␤Met-286). Photoaffinity labeling provides an experimental approach to directly identify amino acids contributing to a drug binding site without determining whether the amino acid makes an important energetic contribution to drug binding. The photolabeled amino acid in ␤M3 was identified previously by mutational analyses as a sensitivity determinant for etomidate and propofol (Krasowski et al., 1998; Siegwart et al., 2002) , and propofol protects against modification of a cysteine substituted at that position (Bali and Akabas, 2004) . Our digestion strategies could not generate the cleavages in the M1-M2 loop necessary to identify photolabeling in ␤M2 at or near ␤2/3Asn265 (␤M2-15), a major determinant of etomidate sensitivity in vitro and in vivo (Jurd et al., 2003; Reynolds et al., 2003) ; therefore, additional studies are required to determine whether labeling is there.
The binding of azietomidate and etomidate in proximity to an amino acid in the ␣ subunit was not predicted by any previous work on etomidate or by the ␣ subunit mutational analyses that identified sensitivity determinants for volatile anesthetics (Mihic et al., 1997; Krasowski et al., 1998; Nishikawa et al., 2002) ; however, the nature of the ␣ subunit did affect the maximum etomidate potentiation of GABA responses or direct activation (HillVenning et al., 1997) , and substitutions at the position in ␣M3 corresponding to ␤Met-286 decreased the EC 50 values for activation by GABA, etomidate, or propofol (Krasowski et al., 1998) .
Although the photolabeling results do not prove directly that ␣Met-236 and ␤Met-286 contribute to a common binding site, consideration of the experimental results in conjunction with homology models of the GABA A R TMD suggests strongly that azietomidate and etomidate both bind in proximity to the two labeled amino acids that are in a pocket at the interface between the ␤ and ␣ subunits. ␣Met-236 and ␤Met-286 were labeled at similar levels (330 and 120 cpm/pmol) and with similar pharmacological specificity; i.e., enhancement by GABA and inhibition by ϳ90% in the presence of 200 M etomidate, consistent with the IC 50 value of 30 M seen for etomidate inhibition at the subunit level. In addition, azietomidate and other aliphatic diazirines preferentially label reactive side chains (Glu, Asp, and Tyr) in the nAChR and in soluble proteins (Pratt et al., 2000; Das et al., 2004; Ziebell et al., 2004) . The lack of labeling of those side chains in ␣M1 (Tyr-225 and Tyr-231) and ␤M3 (Asp-282, Tyr-284, and Glu-298) provides evidence of the structural specificity of labeling and identifies regions in the TMD that do not contribute to the etomidate binding site.
An etomidate binding pocket in GABA A R homology models
We compared the location of the labeled amino acids in two GABA A R homology models, based on the Torpedo nAChR structure (Unwin, 2005) , that differ subtly in the organization of the transmembrane ␣ helices. The first model (Ernst et al., 2005) incorporates a two-amino-acid deletion in the M2-M3 loop of each GABA A R subunit resulting in a loop of four amino acids beginning at ␣1Tyr-282. The second model, which is described in Materials and Methods, limits the M2-M3 loop to five amino acids extending from the conserved proline ␣1Pro-278 to ␣1Ala-283. In the nAChR structure and in both GABA A R models based on that structure, there are potential drug binding sites within aqueous pockets in the TMD that are within each subunit bundle of M1-M4 ␣-helices and are also at subunit interfaces bound by M1/M2 of one subunit and M2/M3 of an adjacent subunit. In the first model (data not shown), ␣ 1 Met-236 in ␣M1 is oriented toward the ␤M3 helix, suggesting an etomidate binding site at the interface of ␤ and ␣ subunits, but the labeled ␤Met-286 is oriented toward the interior of the ␤ subunit transmembrane helical bundle. In this model, the two labeled amino acids contribute to two distinct pockets; however, ␣ 1 Met-236 is in close proximity to residues in ␤M3 (␤Glu-298 and ␤Tyr-299) that were not labeled but would have high intrinsic reactivity for the carbocationreactive intermediate formed during irradiation of azietomidate. The lack of labeling of those reactive residues led us to develop a second homology model differing primarily in the disposition of amino acids in the M2-M3 loop and in M3.
In the homology model in Figure 6 , the labeled amino acids (␣1Met-236 and ␤3Met-286) are ϳ10 Å apart at the interface between the ␤ and ␣ subunits. Their side chains project toward a pocket, and this potential binding site for allosteric modulators in the TMD is at the same ␤-␣ interface as the binding pockets for GABA 50 Å above in the extracellular domain. Azietomidate can be accommodated readily in this pocket, as is shown in supplemental Figure 3 (available at www.jneurosci.org as supplemental material), which presents an expanded stereo view of the interface between the ␤ and ␣ subunits with the amino acids highlighted that project toward the pocket. Because ␤Asp-282 and ␤Met-283, which are positioned on the M3 helix one turn above ␤Met-286, are unlabeled, this suggests that ␤Met-286 defines the extracellular limit of the azietomidate binding site. The etomidate sensitivity determinant at ␤M2-15 (␤1Ser-265/␤2/3Asn-265) is at the level of ␣Met-236, which is accessible from both the intersubunit and intrasubunit pockets. The broad accessibility of ␤M2-15 predicted by this model may account for the fact that propofol does not protect from modification a cysteine substituted at this position, whereas it protects ␤M286C from modification (Bali and Akabas, 2004) . Our model also predicts that ␣M2-15, a volatile anesthetic and alcohol sensitivity determinant (Mihic et al., 1997) and a position where propanethiol modification of a substituted cysteine results in persistent potentiation of GABA responses (Mascia et al., 2000) , will be located equivalently to ␤M2-15 but at ␣-␤ and ␣-␥ subunit interfaces.
A common binding site for agonist potentiation and direct gating Etomidate and azietomidate, in common with most other general anesthetics, act at low concentrations to potentiate responses to submaximal GABA concentrations, with EC 50 values of ϳ2 M under usual assay conditions, and in the absence of GABA they directly activate the GABA A R with EC 50 values of ϳ50 M. Distinct sites for potentiation and direct activation have been proposed to account for the effects of substitutions at ␤M2-15 and at ␤Met-286 that differentially attenuate either potentiation by positive allosteric modulators or direct activation (Moody et al., 1997; Krasowski et al., 1998; Olsen et al., 2004) ; however, these varied phenomena can be accounted for by a mechanism in which etomidate binds to a common site resulting in potentiation or activation. GABA potentiation and direct activation share the same dependence on ␤ subunit isoforms, the same stereoselectivity for etomidate (Tomlin et al., 1998) [and azietomidate (Husain et al., 2003) ], and parallel responses for substitutions at ␤M2-15 Jurd et al., 2003) . In addition, for wild-type GABA A R, concentrations of etomidate up to 100 M produce a progressive decrease of GABA EC 50 values without evidence of saturation, and the data were well-fit by an allosteric model with each GABA A R containing two equivalent etomidate binding sites contributing to direct gating and agonist potentiation (Rusch et al., 2004) . Thus, although the IC 50 value of 30 M for etomidate inhibition of GABA A R photolabeling is close to the EC 50 value for direct gating, the experimental data presented here are consistent with the conclusion that ␣Met-236 as well as ␤Met-286 contribute to a single binding site responsible for potentiation and direct gating and that this binding site is located in the TMD at the interface between the ␤ and ␣ subunits. projecting toward the pocket. Also shown is a Connolly surface representation of azietomidate. b-d, Views of the GABA A R homology model (␤ 3 , cyan; ␣ 1 , yellow; ␥ 2 , green) from perspectives parallel to the membrane surface (b) or looking down the channel (c, d) at levels indicated by the arrows in b. Pockets in the vicinity of the binding sites for etomidate (maroon), GABA (purple), and benzodiazepine (red) are shown as Connolly surfaces. d, Also included are potential intrahelical pockets in ␣ 1 and ␤ 3 (orange), the positions in ␣ 1 M2 and ␣ 1 M3 that as Cys mutants are susceptible to oxidative cross-linking (*) (Jansen and Akabas, 2006) , and the perspective of a (red arrow).
